Influence of apolipoprotein E genotype and dietary α-tocopherol on redox status and C-reactive protein levels in apolipoprotein E3 and E4 targeted replacement mice

British Journal of Nutrition

Volumn 100, Issue 1, 2008, Pages 44-53

  Jofre Monseny, Laia ^a   Huebbe, Patricia ^a   Stange, Inken ^a   Boesch Saadatmandi, Christine ^a   Frank, Jan ^a   Jackson, Kim ^b   Minihane, Anne Marie ^b   Rimbach, Gerald ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b UNIVERSITY OF READING   (United Kingdom)

Author keywords

Tocopherol; Apolipoprotein E polymorphism; C reactive protein; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; C REACTIVE PROTEIN; CATALASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; ISOPROSTANE DERIVATIVE; MITOGENIC AGENT; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVITY; FEMALE; FOOD COMPOSITION; GENOTYPE; LUNG PARENCHYMA; LYMPHOCYTE PROLIFERATION; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK REDUCTION; STRAIN DIFFERENCE; TREATMENT DURATION;

ALPHA-TOCOPHEROL; ANIMALS; ANTIOXIDANTS; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DIET; FEMALE; GLUTATHIONE; HUMANS; LYMPHOCYTE ACTIVATION; MICE; MITOGENS; OXIDATION-REDUCTION; OXIDATIVE STRESS; SPLEEN;

MUS;

EID: 45749140807     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S000711450788634X     Document Type: Article

References (60)

1. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE & Stroehla BC (2002) Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review. Am J Epidemiol 155, 487-495.
2. Song Y, Stampfer MJ & Liu S (2004) Meta-analysis: Apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med 141, 137-147.
3. Mahley RW, Weisgraber KH & Huang Y (2006) Apolipoprotein E4: A causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci U S A 103, 5644-5651.
4. Davignon J, Gregg RE & Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8, 1-21.
5. Wilson PW, Myers RH, Larson MG, Ordovas JM, Wolf PA & Schaefer EJ (1994) Apolipoprotein E alleles, dyslipidemia, and coronary heart disease. The Framingham Offspring Study. JAMA 272, 1666-1671.
6. Miyata M & Smith JD (1996) Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet 14, 55-61.
7. Jofre-Monseny L, de Pascual-Teresa S, Plonka E, Huebbe P, Boesch-Saadatmandi C, Minihane AM & Rimbach G (2007) Differential effects of apolipoprotein E3 and E4 on markers of oxidative status in macrophages. Br J Nutr 97, 864-871.
8. Jofre-Monseny L, Loboda A, Wagner AE, Huebbe P, Boesch-Saadatmandi C, Jozkowitz A, Minihane AM, Dulak J & Rimbach G (2007) Effects of apoE genotype on macrophage inflammation and heme oxygenase-1 expression. Biochem Biophys Res Commun 367, 319-324.
9. Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN & Miller GJ (2001) Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: A prospective study. Lancet 358, 115-119.
10. Talmud PJ, Stephens JW, Hawe E, Demissie S, Cupples LA, Hurel SJ, Humphries SE & Ordovas JM (2005) The significant increase in cardiovascular disease risk in APOEepsilon4 carriers is evident only in men who smoke: Potential relationship between reduced antioxidant status and ApoE4. Ann Hum Genet 69, 613-622.
11. Dietrich M, Hua Y, Block G, Olano E, Packer L, Morrow JD, Hudes M, Abdukeyum G, Rimbach G & Minihane AM (2005) Associations between apolipoprotein E. genotype and circulating F2-isoprostane levels in humans. Lipids 40, 329-334.
12. Minihane AM, Jofre-Monseny L, Olano-Martin E & Rimbach G (2007) ApoE genotype, cardiovascular risk and responsiveness to dietary fat manipulation. Proc Nutr Soc 66, 183-197.
13. Peroutka SJ & Dreon DM (2000) The value of genotyping for apolipoprotein E alleles in relation to vitamin E supplementation. Eur J Pharmacol 410, 161-163.
14. Rimbach G, Minihane AM, Majewicz J, Fischer A, Pallauf J, Virgli F & Weinberg PD (2002) Regulation of cell signalling by vitamin E. Proc Nutr Soc 61, 415-425.
15. Esterbauer H, Schmidt R & Hayn M (1997) Relationships among oxidation of low-density lipoprotein, antioxidant protection, and atherosclerosis. Adv Pharmacol 38, 425-456.
16. Jialal I & Grundy SM (1992) Effect of dietary supplementation with α-tocopherol on the oxidative modification of low density lipoprotein. J Lipid Res 33, 899-906.
17. Pratico D, Tangirala RK, Rader DJ, Rokach J & FitzGerald GA (1998) Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in apoE-deficient mice. Nat Med 4, 1189-1192.
18. Bulger EM, Helton WS, Clinton CM, Roque RP, Garcia I & Maier RV (1997) Enteral vitamin E supplementation inhibits the cytokine response to endotoxin. Arch Surg 132, 1337-1341.
19. Fong JS (1976) α-Tocopherol: Its inhibition on human platelet aggregation. Experientia 32, 639-641.
20. Rosenblat M & Aviram M (2002) Oxysterol-induced activation of macrophage NADPH-oxidase enhances cell-mediated oxidation of LDL in the atherosclerotic apolipoprotein E deficient mouse: Inhibitory role for vitamin E. Atherosclerosis 160, 69-80.
21. Riddell DR, Graham A & Owen JS (1997) Apolipoprotein E inhibits platelet aggregation through the L-arginine:nItric oxide pathway. Implications for vascular disease. J Biol Chem 272, 89-95.
22. Miller ER III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ & Guallar E (2005) Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142, 37-46,
23. Robinson I, de Serna DG, Gutierrez A & Schade DS (2006) Vitamin E in humans: An explanation of clinical trial failure. Endocr Pract 12 576-582.
24. Marklund S & Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47, 469-474.
25. Johansson LH & Borg LA (1988) A spectrophotometric method for determination of catalase activity in small tissue samples. Anal Biochem 174, 331-336.
26. Cohen MB & Duvel DL (1988) Characterization of the inhibition of glutathione reductase and the recovery of enzyme activity in exponentially growing murine leukemia (L1210) cells treated with 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochem Pharmacol 37, 3317-3320.
27. Lawrence RA & Burk RF (1976) Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 71, 952-958.
28. Griffith OW (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal Biochem 106, 207-212.
29. Rimbach G & Pallauf J (1998) Phytic acid inhibits free radical formation in vitro but does not affect liver oxidant or antioxidant status in growing rats. J Nutr 128, 1950-1955.
30. Champney TH, Prado J, Youngblood T, Appel K & McMurray DN (1997) Immune responsiveness of splenocytes after chronic daily melatonin administration in male Syrian hamsters. Immunol. Lett 58: 95-100.
31. Romano-Carratelli C, Bentivoglio C, Nuzzo I, et al. (2002) Effect of protein SV-IV on experimental Salmonella enterica serovar Typhimurium infection in mice. Clin Diagn Lab Immunol 9, 115-125.
32. McGavin JK, Mann JI, Skeaff CM & Chisholm A (2001) Comparison of a vitamin E-rich diet and supplemental vitamin E on measures of vitamin E status and lipoprotein profile. Eur J Clin Nutr 55, 555-561.
33. Haddy N, De Bacquer D, Chemaly MM, et al. (2002) The importance of plasma apolipoprotein E concentration in addition to its common polymorphism on inter-individual variation in lipid levels: Results from Apo Europe. Eur J Hum Genet 10, 841-850.
34. Schiele F, De Bacquer D, Vincent-Viry M, et al. (2000) Apolipoprotein E serum concentration and polymorphism in six European countries: The ApoEurope Project. Atherosclerosis 152, 475-488.
35. Gomez-Coronado D, Entrala A, Alvarez JJ, Ortega H, Olmos JM, Castro M, Sastre A, Herrera E & Lasuncion MA (2002) Influence of apolipoprotein E polymorphism on plasma vitamin A and vitamin E levels. Eur J Clin Invest 32, 251-258.
36. Lodge JK, Hall WL, Jeanes YM & Proteggente AR (2004) Physiological factors influencing vitamin E biokinetics. Ann N Y Acad Sci 1031, 60-73.
37. Li X, Kan HY, Lavreatiadou S, Krieger M & Zannis V (2002) Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI. The amino-terminal 1-165 domain of ApoE suffices for receptor binding. J Biol Chem 277, 21149-21157.
38. Mardones P & Rigotti A (2004) Cellular mechanisms of vitamin E uptake: relevance in α-tocopherol metabolism and potential implications for disease. J Nutr Biochem 15, 252-260.
39. Mardones P, Strobel P, Miranda S, Leighton F, Quinones V, Amigo L, Rozowski J, Krieger M & Rigotti A (2002) α-Tocopherol metabolism is abnormal in scavenger receptor class B type I (SR-BI -deficient mice. J Nutr 132, 443-449.
40. Kolleck I, Schlame M, Fechner H, Looman AC, Wissel H & Rustow B (1999) HDL is the major source of vitamin E for type II pneumocytes. Free Radic Biol Med 27, 882-890.
41. Hirano K, Yamashita S, Nakagawa Y, et al. (1999) Expression of human scavenger receptor class B type I in cultured human monocyte-derived macrophages and atherosclerotic lesions. Circ Res 85, 108-116.
42. Mas E, Dupuy AM, Artero S, Portet F, Cristol JP, Ritchie K & Touchon J (2006) Functional Vitamin E deficiency in ApoE4 patients with Alzheimer's disease. Dement Geriatr Cogn Disord 21, 198-204.
43. Fernandes MA, Proenca MT, Nogueira AJ, Grazina MM, Oliveira LM, Fernandes AI, Santiago B, Santana I & Oliveira CR (1999) Influence of apolipoprotein E genotype on blood redox status of Alzheimer's disease patients. Int J Mol Med 4, 179-186.
44. Ramassamy C, Averill D, Beffert U, et al. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radic Biol Med 27, 544-553.
45. Ophir G, Amariglio N, Jacob-Hirsch J, Elkon R, Rechavi G & Michaelson DM (2005) Apolipoprotein E4 enhances brain inflammation by modulation of the NF-κB signaling cascade. Neurobiol Dis 20, 709-718.
46. Patrono C & FitzGerald GA (1997) Isoprostanes: Potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 17, 2309-2315.
47. Sullivan PM, Mezdour H, Aratani Y, Knouff C, Najib J, Reddick RL, Quarfordt SH & Maeda N (1997) Targeted replacement of the mouse apolipoprotein E gene with the common human APOE3 allele enhances diet-induced hypercholesterolemia and atherosclerosis. J Biol Chem 272, 17972-17980.
48. Talmud PJ (2007) Gene-environment interaction and its impact on coronary heart disease risk. Nutr Metab Cardiovasc Dis 17, 148-152.
49. Lahoz C, Schaefer EJ, Cupples LA, Wilson PW, Levy D, Osgood D, Parpos S, Pedro-Botet J, Daly JA & Ordovas JM (2001) Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. Atherosclerosis 154, 529-537.
50. Zhou X, Nicoletti A, Elhage R & Hansson GK (2000) Transfer of CD4(+) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102, 2919-2922.
51. Major AS, Fazio S & Linton MF (2002) B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 22, 1892-1898.
52. Kelly ME, Clay MA, Mistry MJ, Hsieh-Li HM & Harmony JA (1994) Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: Production of interleukin 2 with reduced biological activity. Cell Immunol 159, 124-139.
53. Mistry MJ, Clay MA, Kelly ME, Steiner MA & Harmony JA (1995) Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary. Cell Immunol 160, 14-23.
54. Laskowitz DT, Lee DM, Schmechel D & Staats HF (2000) Altered immune responses in apolipoprotein E-deficient mice. J Lipid Res 41 613-620.
55. de Ferranti SD & Rifai N (2007) C-reactive protein: A nontraditional serum marker of cardiovascular risk. Cardiovasc Pathol 16, 14-21.
56. Paffen E & DeMaat MP (2006) C-reactive protein in atherosclerosis: A causal factor? Cardiovasc Res 71, 30-39.
57. Marz W, Scharnagl H, Hofmann MM, Boehm BO & Winkelmann BR (2004) The apolipoprotein E polymorphism is associated with circulating C-reactive protein (the Ludwigshafen risk and cardiovascular health study). Eur Heart J 25, 2109-2119.
58. Kahri J, Soro-Paavonen A, Ehnholm C & Taskinen MR (2006) ApoE polymorphism is associated with C-reactive protein in low-HDL family members and in normolipidemic subjects. Mediators Inflamm 2006 12587.
59. Judson R, Brain C, Dain B, Windemuth A, Ruano G & Reed C (2004) New and confirmatory evidence of an association between APOE genotype and baseline C-reactive protein in dyslipidemic individuals. Atherosclerosis 177, 345-351.
60. Scheurig AC, Thorand B, Fischer B, Heier M & Koenig W (2007) Association between the intake of vitamins and trace elements from supplements and C-reactive protein: Results of the MONICA/KORA Augsburg study. Eur J Clin Nutr (Epublication ahead of print version 21 February 2007).